

FORM PTO-1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. P-IX 2405	SERIAL NO.. 08/790,540
	APPLICANT William D. Huse	
	FILING DATE 01/30/97	GROUP <i>1644</i> 1815 <i>1805</i>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
<i>W</i>	5,225,539	07/06/93	Winter, Gregory P.	530	387.3	—
	5,264,563	11/23/93	Huse, William D.	536	25.3	—
	5,523,388	06/04/96	Huse, William D.	536	22.1	—
	5,585,089	12/17/96	Queen et al.	424	133.1	—

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
	0 451 216 B1	10/16/91	Europe	C12P21	08	—
	0 682,040 A1	11/15/95	Europe	C07K16	46	—

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	Brooks et al., "Integrin $\alpha\text{v}\beta 3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels" <u>Cell</u> 79:1157-1164 (1994)
	Cheresh, D.A., "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor" <u>Proc. Natl. Acad. Sci. USA</u> 84:6471-6475 (1987)
<i>ML</i>	Cheresh and Spiro, "Biosynthetic and Functional Properties of an Arg-Gly-Asp-directed Receptor Involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen, and von Willebrand Factor" <u>J. Biol. Chem.</u> 262(36):17703-17711 (1987)

EXAMINER <i>Philip Gamble 8/31/97</i>	DATE CONSIDERED
------------------------------------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. P-IX 2405	SERIAL NO.. 08/790,540
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT William D. Huse	
	FILING DATE 01/30/97	GROUP 1815 1644 1006

Mo		Choi et al., "Inhibition of neointimal hypersplasia by blocking $\alpha V\beta 3$ integrin with a small peptide antagonist GpenGRGDSPCA" <u>J. Vascular Surg.</u> , 19:125-134 (1994)
		Chothia et al., "Canonical Structures for the Hypervariable Regions of Immunoglobulins" <u>J. Mol. Biol.</u> 196:901-917 (1987)
		Day, E.D., <u>Advanced Immunochemistry</u> , Second Ed., Wiley-Liss, Inc., New York, NY (1990)
		Devlin et al., "Random Peptide Libraries: A Source of Specific Protein Binding Molecules" <u>Science</u> 249:404-406, (1990)
		Glaser et al., "Antibody Engineering by Condon-Based Mutagenesis in a Filamentous Phage Vector System" <u>J. Immunol.</u> 149:3903-3913 (1992)
		Huse, W.D., "Combinatorial Antibody Expression Libraries in Filamentous Phage" In: Antibody Engineering: A Practical Guide, C.A.K. Borrebaeck, ed. W.H. Freeman and Co., Publishers, New York, pp. 103-120 (1991)
		Huse et al., "Application of a Filamentous Phage pVIII Fusion Protein System Suitable for Efficient Production, Screening, and Mutagenesis of F(ab) Antibody Fragments" <u>J. Immunol.</u> 149:3914-3920 (1992)
		Huston et al., "Antigen Recognition and Targeted Delivery by the Single-Chain Fv" <u>Cell Biophysics</u> , 22:189-224 (1993)
		Kabat et al., U.S. Dept. of Health and Human Services, "Sequences of Proteins of Immunological Interest" (1983)
		MacCallum et al., "Antibody-antigen Interactions: Contact Analysis and Binding Site Topography" <u>J. Mol. Biol.</u> 262:732-745 (1996)
		Padlan, Eduardo A., "A Possible Procedure For Reducing the Immunogenicity of Antibody Variable Domains While Preserving Their Ligand-Binding Properties" <u>Molecular Immunol.</u> 28(4/5):489-498 (1991)
M		Plückthun and Skerra, "Antibodies from <i>Escherichia coli</i> " <u>Meth. Enzymol.</u> 178:497-515 (1989)

EXAMINER Philip Gambel 8/31/97	DATE CONSIDERED
-----------------------------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. P-IX 2405	SERIAL NO.. 08/790,540
	APPLICANT William D. Huse	
	FILING DATE 01/30/97	GROUP 1815 ¹⁶⁴⁴ 1805
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		

<i>M</i>	"Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man," Clark, M. (ed.), Nottingham, England: Academic Titles (1993)
<i>N</i>	Rosok et al., "A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab" <u>J. Biol. Chem.</u> 271:22611-22618 (1996)
<i>N</i>	Singer et al., "Optimal Humanization of 1B4, an Anti-CD18 Murine Monoclonal Antibody, is Achieved by Correct Choice of Human V-Region Framework Sequences" <u>J. Immunol.</u> 150(7):2844-2857 (1993)
<i>N</i>	Yelton et al., "Affinity Maturation of the BR96 Anti-Carcinoma Antibody by Condon-Based Mutagenesis" <u>J. Immunol.</u> 155:1994-2003 (1995)

EXAMINER <i>PHILIP GAMMEL 8/3/97</i>	DATE CONSIDERED
-----------------------------------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.